Talis Biomedical CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
10-Q: Talis Biomedical Corporation Signals Imminent Bankruptcy Filing After Strategic Alternatives Fail
Talis Biomedical Corporation is preparing to file for Chapter 11 bankruptcy after failing to find a viable strategic alternative and ceasing all research and development activities.
10-Q: Talis Biomedical Reports Q1 2024 Results, Continues Strategic Review Amidst Cost-Cutting Measures
Talis Biomedical Corporation reports a net loss of $13.0 million for Q1 2024 and continues to explore strategic alternatives while significantly reducing operating expenses.